Group 1 - The stock price of Fuxiang Pharmaceutical on August 27 was 10.05 yuan, down 0.59 yuan or 5.55% from the previous trading day [1] - The company primarily engages in the research, production, and sales of active pharmaceutical ingredients and intermediates for anti-infection drugs, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein [1] - Fuxiang Pharmaceutical is the largest supplier of sulbactam globally and the only domestic supplier in the sulbactam field certified by international standards [1] Group 2 - According to the company's 2025 semi-annual report, it achieved operating revenue of 515 million yuan in the first half of the year, a year-on-year decrease of 24.6%, with a net profit attributable to the parent company of -6.91 million yuan, an improvement from a loss of 22.46 million yuan in the same period last year [1] - In the lithium battery electrolyte additive business, the company has established an annual production capacity of 8,000 tons for VC products and 3,700 tons for FEC products [1] - The company has a production capacity of 1,200 tons per year in the microbial protein sector and is constructing a project with an annual capacity of 20,000 tons [1] Group 3 - On August 27, the net inflow of main funds into Fuxiang Pharmaceutical was 17.78 million yuan, accounting for 0.39% of the circulating market value; over the past five days, the cumulative net inflow was 20.96 million yuan, representing 0.46% of the circulating market value [2]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Clarithromycin suspension, which is expected to enhance the company's product offerings in the anti-infection drug category and improve its overall competitiveness [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Clarithromycin suspension by the National Medical Products Administration [1]. - The application for the marketing authorization of Clarithromycin suspension was submitted in December 2023 and was accepted, with the registration certificate obtained in August 2025 [1]. Group 2: Indications and Market Potential - Clarithromycin is indicated for treating infections caused by pathogens sensitive to it, including upper respiratory infections, lower respiratory infections, skin and soft tissue infections, and acute otitis media [2]. - The estimated sales revenue for Clarithromycin in public medical institutions in China is approximately RMB 1.123 billion in 2024 [2]. - The approval of Clarithromycin suspension will enrich the company's anti-infection drug portfolio [2].